The melanoma immunotherapies include the cytokine therapies consisting of IFN-α and IL-2 [61-63] and inhibitors to CTLA-4 (ipilimumab) and PD-1 (nivolumab, lambrolizumab and pembrolizumab) [47, 51, 52]. Here, IL2 is linked to melanoma.